Description: Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Home Page: impelpharma.com
IMPL Technical Analysis
201 Elliott Avenue West
Seattle,
WA
98119
United States
Phone:
206 568 1466
Officers
| Name | Title |
|---|---|
| Mr. Adrian Adams | Chairman & CEO |
| Dr. John D. Hoekman Ph.D. | Co-Founder and Chief Technology & Devel. Officer |
| Dr. John H. Leaman M.D. | Chief Financial & Bus. Officer |
| Mr. Leonard S. Paolillo | Chief Commercial Officer |
| Ms. Jennifer L. Berman | VP of Marketing |
| Ms. Patty Billingsley | VP of Sales |
| Ms. Sarah Wille | VP of HR |
| Dr. Stephen Bevan Shrewsbury M.B. Ch.B., M.D. | Chief Medical Officer |
| Dr. Lynn C. Gold Ph.D. | Sr. VP of Regulatory |
| Mr. Scott Youmans | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 18.4568 |
| Price-to-Sales TTM: | 10.3666 |
| IPO Date: | 2021-04-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 129 |